Behavioral and Biochemical Implications of Dendrimeric Rivastigmine in Memory-Deficit and Alzheimer's Induced Rodents
- PMID: 31257860
- DOI: 10.1021/acschemneuro.9b00286
Behavioral and Biochemical Implications of Dendrimeric Rivastigmine in Memory-Deficit and Alzheimer's Induced Rodents
Abstract
Exploration of dendrimers for effective drug delivery is giving promising results. The present study was designed and performed to explore the dendrimeric (polyamidoamine-lactoferrin; PAMAM-Lf) formulations for the effective rivastigmine (RIV) delivery against the Alzheimer's induced animal model using lactoferrin as the targeting ligand. RIV delivery through PAMAM-Lf conjugates was highly efficient in the Alzheimer's induced animal model. PAMAM-Lf conjugates also efficiently improved behavioral responses against the chemical memory deficit animal model as well as the Alzheimer's induced animal model, separately. Behavioral responses revealed that motor and spatial memories were significantly improved (p < 0.005) over those from RIV alone. The latency time of PAMAM-Lf-RIV was 1.3 times higher over that of the pure RIV in the rotarod protocol, while it was 2.1-fold reduced in the Morris water maze test. The study also attempted to explore the mechanistic aspect of improved efficacy through biochemical evaluation (AChE histo-enzymology), which reveals that levels of dopamine and its metabolite 3,4-dihydroxyphenylacetic acid were unaffected, but AChE activity was improved for all forms of RIV. Conclusively, PAMAM-Lf conjugates were able to deliver RIV effectively against the Alzheimer's induced animal model. This was further strengthened with the positive results obtained with the behavioral studies of memory-deficit animals and disease-induced animals. The study is among the first studies which report RIV delivery against the Alzheimer's induced animal model using PAMAM dendrimers.
Keywords: Alzheimer’s; PAMAM; brain delivery; dendrimers.
Similar articles
-
Boosted Memory and Improved Brain Bioavailability of Rivastigmine: Targeting Effort to the Brain Using Covalently Tethered Lower Generation PAMAM Dendrimers with Lactoferrin.Mol Pharm. 2018 Oct 1;15(10):4538-4549. doi: 10.1021/acs.molpharmaceut.8b00537. Epub 2018 Aug 29. Mol Pharm. 2018. PMID: 30156844
-
Lactoferrin Coupled Lower Generation PAMAM Dendrimers for Brain Targeted Delivery of Memantine in Aluminum-Chloride-Induced Alzheimer's Disease in Mice.Bioconjug Chem. 2019 Oct 16;30(10):2573-2583. doi: 10.1021/acs.bioconjchem.9b00505. Epub 2019 Sep 25. Bioconjug Chem. 2019. PMID: 31553175
-
Preparation and characterization of brain-targeted polymeric nanocarriers (Frankincense-PMBN-lactoferrin) and in-vivo evaluation on an Alzheimer's disease-like rat model induced by scopolamine.Brain Res. 2024 Jan 1;1822:148622. doi: 10.1016/j.brainres.2023.148622. Epub 2023 Oct 11. Brain Res. 2024. PMID: 37832760
-
Main Plant Extracts' Active Properties Effective on Scopolamine-Induced Memory Loss.Am J Alzheimers Dis Other Demen. 2017 Nov;32(7):418-428. doi: 10.1177/1533317517715906. Epub 2017 Jun 23. Am J Alzheimers Dis Other Demen. 2017. PMID: 28643520 Free PMC article. Review.
-
Animal models in the drug discovery pipeline for Alzheimer's disease.Br J Pharmacol. 2011 Oct;164(4):1285-300. doi: 10.1111/j.1476-5381.2011.01299.x. Br J Pharmacol. 2011. PMID: 21371009 Free PMC article. Review.
Cited by
-
Breaking Barriers in Alzheimer's Disease: the Role of Advanced Drug Delivery Systems.AAPS PharmSciTech. 2024 Sep 5;25(7):207. doi: 10.1208/s12249-024-02923-6. AAPS PharmSciTech. 2024. PMID: 39237748 Review.
-
Dendrimers and Derivatives as Multifunctional Nanotherapeutics for Alzheimer's Disease.Pharmaceutics. 2023 Mar 24;15(4):1054. doi: 10.3390/pharmaceutics15041054. Pharmaceutics. 2023. PMID: 37111540 Free PMC article. Review.
-
Dendrimers in Alzheimer's Disease: Recent Approaches in Multi-Targeting Strategies.Pharmaceutics. 2023 Mar 10;15(3):898. doi: 10.3390/pharmaceutics15030898. Pharmaceutics. 2023. PMID: 36986759 Free PMC article. Review.
-
Targeting the Pathological Hallmarks of Alzheimer's Disease Through Nanovesicleaided Drug Delivery Approach.Curr Drug Metab. 2022;23(9):693-707. doi: 10.2174/1389200223666220526094802. Curr Drug Metab. 2022. PMID: 35619248
-
Lactoferrin, a multi-functional glycoprotein: Active therapeutic, drug nanocarrier & targeting ligand.Biomaterials. 2020 Dec;263:120355. doi: 10.1016/j.biomaterials.2020.120355. Epub 2020 Sep 9. Biomaterials. 2020. PMID: 32932142 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical